This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Xyrem

Jazz Pharmaceuticals plc

Drug Names(s): sodium oxybate

Description: BioMedTracker has separate drug profiles for sodium oxybate. Please also see JZP-6.

Xyrem (sodium oxybate) is a form of gamma hydroxybutyrate (GHB), a chemical compound structurally similar to the inhibitory brain neurotransmitter gamma-aminobutyric acid (GABA). Although its precise mechanism of action is not known, it is thought to act as an inhibitory neuromodulator within the central nervous system by binding to specific GHB receptors or GABA B receptors. Xyrem is the first and only FDA-approved medication for the treatment of cataplexy associated with narcolepsy, a condition characterized by the sudden loss of muscle control in response to extreme emotional stimuli such as laughter, anger, or surprise.

Deal Structure: In March 2010, Lonza, Jazz's current sole supplier of sodium oxybate, the active ingredient in both Xyrem and JZP-6, formally notified Jazz that the companies' agreement for the supply of sodium oxybate will terminate on December 31, 2011, at the end of its current term as Lonza intends to close the plant where it manufactures sodium oxybate. Lonza is contractually obligated to supply Jazz's requirements of sodium oxybate through December 31, 2011. Jazz subsequently entered into an agreement with a new supplier, Siegfried, in order to help ensure that it has an uninterrupted supply of sodium oxybate.

Jazz and UCB
UCB acquired the licence to distribute Xyrem in Europe from Orphan Medical (recently acquired by Jazz Pharmaceuticals). Xyrem is marketed in the U.S. by Jazz Pharmaceuticals.

In October, 2006, UCB announced the signing of an expanded product license agreement for Xyrem. Under the agreement, UCB obtains the right to commercialize Xyrem for the treatment...See full deal structure in Biomedtracker

Partners: UCB SA Valeant Pharmaceuticals International, Inc.


Xyrem News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug